Prevalence of Fabry disease in men with tinnitus and sensorineural hearing loss.
暂无分享,去创建一个
M. Chovanec | R. Holý | Klára Procházková | J. Astl | B. Gál | B. Streubel | A. Linhart | D. Kalfeřt | T. Hložková | Frantiska Hybnerova | Denisa Ebelova
[1] R. Garnotel,et al. Maladie de Fabry : quand y penser ? , 2020 .
[2] C. Wanner,et al. Characterization of vertigo and hearing loss in patients with Fabry disease , 2018, Orphanet Journal of Rare Diseases.
[3] A. Linhart,et al. Fabry disease, an overview and the most common neurological manifestations , 2018 .
[4] R. Holý,et al. Hyperbaric oxygen therapy in tinnitus with normal hearing in association with combined treatment. , 2016, Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc.
[5] J. Kuusisto,et al. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease , 2015, Drug design, development and therapy.
[6] G. Paludetti,et al. Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy. , 2010, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.
[7] Shing‐Jong Lin,et al. High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population , 2009, Circulation. Cardiovascular genetics.
[8] Y. Chien,et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later‐onset GLA mutation c.936+919G>A (IVS4+919G>A) , 2009, Human mutation.
[9] P. Elliott,et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa , 2007, Heart.
[10] A. Mehta,et al. Hearing loss in Fabry disease: data from the Fabry Outcome Survey , 2006, European journal of clinical investigation.
[11] R. Desnick,et al. High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.
[12] M. Audran,et al. Fabry disease: a review. , 2004, Joint, bone, spine : revue du rhumatisme.
[13] A. Mehta,et al. Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy , 2003, Journal of Inherited Metabolic Disease.
[14] K. Macdermot,et al. Hearing improvement in patients with Fabry disease treated with agalsidase alfa , 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.
[15] S. Packman,et al. Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.
[16] K. Macdermot,et al. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males , 2001, Journal of medical genetics.
[17] S. Mulgaonkar,et al. Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance. , 2000, Transplantation.
[18] G. Hughes,et al. Sudden sensorineural hearing loss. , 1996, Otolaryngologic clinics of North America.
[19] H. Schuknecht,et al. Cochlear Pathology in Presbycusis , 1993, The Annals of otology, rhinology, and laryngology.
[20] M. Paparella,et al. Otologic Histopathology of Fabry's Disease , 1989, The Annals of otology, rhinology, and laryngology.
[21] S. Hegemann,et al. Fabry disease and the ear , 2006 .
[22] F. Akdaş,et al. Idiopathic sudden sensorineural hearing loss , 2006 .
[23] D. Germain. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. , 2001, Contributions to nephrology.
[24] Mattox De,et al. Idiopathic sudden sensorineural hearing loss. , 1989, The American journal of otology.